Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04593121 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT04593121 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 84 participants.
The verdict
NCT04593121, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The primary objective is to determine the safety and tolerability of single and multiple ascending subcutaneous (SC) doses and a single intravenous (IV) dose of BIIB107 in healthy adult participants. The secondary objectives are to characterize the single-dose pharmacokinetic (PK) of SC and IV BIIB107 in healthy adult participants and to characterize the multiple-dose PK of SC BIIB107 in healthy adult participants.
Interventions
- DRUG Placebo
- DRUG BIIB107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2020-10-30 |
| Est. Completion | 2024-03-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04593121
The ClinicalTrials.gov registry entry for NCT04593121 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04593121 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04593121 about?
NCT04593121 is a clinical study titled "Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants". The primary objective is to determine the safety and tolerability of single and multiple ascending subcutaneous (SC) doses and a single intravenous (IV) dose of BIIB107 in healthy adult participants. The secondary objectives are to characterize the single-dose pharmacokinetic (PK) of SC and IV BIIB1...
What is the current status of trial NCT04593121?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2020-10-30. Estimated completion is 2024-03-05.
What interventions are being tested in trial NCT04593121?
The interventions under investigation include: Placebo (DRUG), BIIB107 (DRUG).
Who is sponsoring clinical trial NCT04593121?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.